Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Yescarta / axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy as of June 2023

MARA Rating Company December 16, 2025

Baricitinib for treating moderate to severe atopic dermatitis as of March 2021

MARA Rating Company December 16, 2025

Survodutide for obesity treatment as of July 2025

MARA Rating Company December 16, 2025

Retatrutide for obesity ± Metabolic Disorders as of July 2025

MARA Rating Company December 16, 2025

Orforglipron for obesity and Type 2 Diabetes as of July 2025

MARA Rating Company December 16, 2025

Cagrilintide-semaglutide for treating obesity with or without type 2 diabetes as of July 2025

MARA Rating Company December 16, 2025

Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours as of January 2025

MARA Rating Company December 16, 2025

Apalutamide / erleada for treating high-risk hormone-relapsed nonmetastatic prostate cancer as of October 2021

MARA Rating Company December 16, 2025

Erleada / apalutamide for treating hormone-sensitive metastatic prostate cancer as of October 2021

MARA Rating Company December 16, 2025

Apixaban / eliquis for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation as of July 2021

MARA Rating Company December 16, 2025